EPISODE · Feb 18, 2025 · 7 MIN
60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoffrey Dow on Expanding Malaria Prevention & Beyond
from Small Stocks, Big Money · host RedChip Companies
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60P is a client of RedChip. Visit www.redchip.com/stocks/sxtp to learn more.
What this episode covers
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60P is a client of RedChip. Visit www.redchip.com/stocks/sxtp to learn more.
NOW PLAYING
60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoffrey Dow on Expanding Malaria Prevention & Beyond
No transcript for this episode yet
Similar Episodes
Apr 29, 2025 ·12m
Apr 27, 2025 ·11m
Apr 24, 2025 ·11m
Apr 22, 2025 ·14m
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m